Immunomedics appoints Charles Baum to board
Dr. Baum is President, CEO and Board Member of Mirati Therapeutics since November 2012.
Prior to joining Mirati, Dr. Baum was Senior Vice President for Biotherapeutic Clinical Research at Pfizer and served as the Head of Oncology Development and as Chief Medical Officer for Pfizer’s Biotherapeutics and Bioinnovation Center.
Dr. Baum was responsible for the development of the oncology portfolio.
Previously, he was responsible for the development of several oncology compounds at Schering-Plough. ■